Fast Facts for Board Review

Biologics for Psoriasis

Cutis. 2016 March;97(3)
Author and Disclosure Information
PDF Download

 

3. Which biologic has been shown to worsen existing Crohn disease?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

Pages

Recommended Reading

Minimal disease activity criteria in PsA fall short
MDedge Dermatology
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis
MDedge Dermatology
Don’t overlook topical tazarotene for psoriasis
MDedge Dermatology
How to Manage Psoriasis Safely in Pregnant Women
MDedge Dermatology
Fresh evidence of methotrexate efficacy in psoriatic arthritis
MDedge Dermatology
Sparse, poor evidence supports fumarates for psoriasis
MDedge Dermatology
Atopic Dermatitis Treatments Moving Forward: Report From the AAD Meeting
MDedge Dermatology
Ixekizumab approved for plaque psoriasis
MDedge Dermatology
Ustekinumab Linked to More Outpatient Visits and Greater Pharmacy Costs Versus Adalimumab in Psoriasis Patients
MDedge Dermatology
Biologics for Pediatric Psoriasis Patients?
MDedge Dermatology

Related Articles

  • Fast Facts for Board Review

    Allergic Contact Dermatitis, Part 4

    Author:
    Laura Doerfler, MD
    William W. Huang, MD, MPH

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Fast Facts for Board Review

    Viruses, Part 2: RNA Viruses

    Author:
    Jenna O'Neill, MD

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Fast Facts for Board Review

    Genetic Pathways, Part 2

    Author:
    Alyssa Daniel, MD
    Publish date: December 29, 2015

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...